Accueil   Diary - News   All news bioMérieux acquires a majority stake in Hybiome

bioMérieux acquires a majority stake in Hybiome

And strengthens its presence both in China and in the immunoassay market


bioMérieux, a world leader in the field of in vitro diagnostics, today announces the acquisition of a majority holding in Suzhou Hybiome Biomedical Engineering Co.Ltd. This announcement follows the acquisition of a minority stake in July 2018. Founded in 2009 and based in Suzhou (China), Hybiome is specialized in automated immunoassay tests. The company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments and software) cleared by the China Food and Drug Administration (CFDA).

Read the press release